BB
BOLD

BB Biotech’s Audentes Therapeutics, Inc BOLD Stock Holding History

BB Biotech’s Portfolio BOLD Stock Details BOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$53.4M Buy
1,369,604
+600,200
+78% +$17.2M 1.34% 25
2018
Q4 		$16.4M Buy
+769,404
New +$19.9M 0.53% 30

Other funds holding BOLD

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

BB Biotech's BOLD Position: Q1 2019 in Review

BB Biotech increased its Audentes Therapeutics, Inc (BOLD) stake by 78% in Q1 2019, buying an estimated $17.2M and bringing the position to 1,369,604 shares worth $53.4M. The position accounts for 1.34% of the portfolio, ranked #25.

BB Biotech first reported a position in BOLD in Q4 2018 and has held it in 2 quarters since. 139 funds tracked by Wall St. Rank hold BOLD as of Q1 2019.

  • BB Biotech held 1,369,604 shares of Audentes Therapeutics, Inc worth $53.4M as of Q1 2019.
  • BB Biotech bought 600,200 Audentes Therapeutics, Inc shares in Q1 2019, an estimated $17.2M.
  • Audentes Therapeutics, Inc made up 1.34% of BB Biotech's portfolio in Q1 2019, its #25 holding.
  • BB Biotech first reported a position in Audentes Therapeutics, Inc in Q4 2018 and has held it in 2 quarters since.
  • 139 funds tracked by Wall St. Rank held Audentes Therapeutics, Inc as of Q1 2019.

Based on BB Biotech's 13F filing for Q1 2019, filed 13 May 2019.